Immune Checkpoint Inhibitor Therapy Information
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Immunotherapy news has been making waves in Taiwan recently. There are many opinions and perspectives on this topic. In a civil society, rational monitoring and discussion is a wonderful thing, and it is through such discourse that systems become more robust.
The following is a brief summary of information on immune checkpoint inhibitor therapy, based on data from (NH)ClinicalTrial.gov as of December 2015.
Symbol Key:
- ◎ Approved for use in Japan
- O Phase 2 or Phase 3 clinical trial in progress or completed in Japan
- ＊ Phase 2 or Phase 3 clinical trial in progress or completed overseas
| Cancer Type | Status |
|---|---|
| Brain Tumor | ＊ |
| Laryngeal Cancer | O |
| Lung Cancer | ◎ OPDIVO / ＊ |
| Breast Cancer | ＊ |
| Gastric Cancer | O |
| Esophageal Cancer | O |
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4